Latest & greatest articles for tuberculosis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on tuberculosis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on tuberculosis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for tuberculosis

1. Community-wide Screening for Tuberculosis in a High-Prevalence Setting. (PubMed)

Community-wide Screening for Tuberculosis in a High-Prevalence Setting. The World Health Organization has set ambitious targets for the global elimination of tuberculosis. However, these targets will not be achieved at the current rate of progress.We performed a cluster-randomized, controlled trial in Ca Mau Province, Vietnam, to evaluate the effectiveness of active community-wide screening, as compared with standard passive case detection alone, for reducing the prevalence of tuberculosis (...) . Persons 15 years of age or older who resided in 60 intervention clusters (subcommunes) were screened for pulmonary tuberculosis, regardless of symptoms, annually for 3 years, beginning in 2014, by means of rapid nucleic acid amplification testing of spontaneously expectorated sputum samples. Active screening was not performed in the 60 control clusters in the first 3 years. The primary outcome, measured in the fourth year, was the prevalence of microbiologically confirmed pulmonary tuberculosis among

2019 NEJM

2. Interventions for the Diagnosis of Tuberculosis: Clinical Effectiveness and Guidelines

Interventions for the Diagnosis of Tuberculosis: Clinical Effectiveness and Guidelines Interventions for the Diagnosis of Tuberculosis: Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Interventions for the Diagnosis of Tuberculosis: Clinical Effectiveness and Guidelines Interventions for the Diagnosis of Tuberculosis: Clinical Effectiveness and Guidelines Last updated: July 2, 2019 Project Number: RA1044-000 Product Line: Research Type: Devices and Systems Report (...) Type: Reference List Result type: Report Question What is the clinical effectiveness of interventions used for the diagnosis of tuberculosis? What are the evidence-based guidelines regarding the diagnosis of tuberculosis? Key Message One health technology assessment and fourteen systematic reviews (twelve with meta-analysis) were identified regarding the clinical effectiveness of interventions used to diagnose tuberculosis. In addition, seven evidence-based guidelines were identified regarding

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

3. Interventions for the Treatment or Management of Tuberculosis: Clinical Effectiveness and Guidelines

Interventions for the Treatment or Management of Tuberculosis: Clinical Effectiveness and Guidelines Interventions for the Treatment or Management of Tuberculosis: Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Interventions for the Treatment or Management of Tuberculosis: Clinical Effectiveness and Guidelines Interventions for the Treatment or Management of Tuberculosis: Clinical Effectiveness and Guidelines Last updated: July 8, 2019 Project Number: RA1045-000 (...) Product Line: Research Type: Devices and Systems Report Type: Reference List Result type: Report Question What is the clinical effectiveness of interventions used to treat or manage individuals with tuberculosis? What are the evidence-based guidelines regarding the treatment or management of individuals with tuberculosis? Key Message Nine systematic reviews (eight with meta-analysis) and four evidence-based guidelines were identified regarding the treatment or management of individuals

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

4. Interventions Used to Screen for Tuberculosis: Clinical Effectiveness and Guidelines

Interventions Used to Screen for Tuberculosis: Clinical Effectiveness and Guidelines Interventions Used to Screen for Tuberculosis: Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Interventions Used to Screen for Tuberculosis: Clinical Effectiveness and Guidelines Interventions Used to Screen for Tuberculosis: Clinical Effectiveness and Guidelines Last updated: June 24, 2019 Project Number: RA1043-000 Product Line: Research Type: Devices and Systems Report Type (...) : Reference List Result type: Report Question What is the clinical effectiveness of interventions used to screen individuals for tuberculosis? What are the evidence-based guidelines regarding the screening of individuals for tuberculosis? Key Message Twelve systematic reviews (eight with meta-analysis) were identified regarding the clinical effectivenessof interventions used to screen individuals for tuberculosis. In addition, four evidence-based guidelines were identified regarding the screening

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

5. Pretomanid - For treatment-resistant forms of tuberculosis

Pretomanid - For treatment-resistant forms of tuberculosis Drug Approval Package: Pretomanid U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: Pretomanid Company: The Global Alliance for TB Drug Development, Inc. (TB Alliance) Application Number: 212862 Approval Date: 08/14/2019 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF) FDA Application

2019 FDA - Drug Approval Package

6. Abdominal ultrasound for diagnosing abdominal tuberculosis or disseminated tuberculosis with abdominal involvement in HIV-positive individuals. (PubMed)

Abdominal ultrasound for diagnosing abdominal tuberculosis or disseminated tuberculosis with abdominal involvement in HIV-positive individuals. Accurate diagnosis of tuberculosis in people living with HIV is difficult. HIV-positive individuals have higher rates of extrapulmonary tuberculosis and the diagnosis of tuberculosis is often limited to imaging results. Ultrasound is such an imaging test that is widely used as a diagnostic tool (including point-of-care) in people suspected of having (...) abdominal tuberculosis or disseminated tuberculosis with abdominal involvement.To determine the diagnostic accuracy of abdominal ultrasound for detecting abdominal tuberculosis or disseminated tuberculosis with abdominal involvement in HIV-positive individuals.To investigate potential sources of heterogeneity in test accuracy, including clinical setting, ultrasound training level, and type of reference standard.We searched for publications in any language up to 4 April 2019 in the following databases

2019 Cochrane

7. Management of drug-resistant tuberculosis. (PubMed)

Management of drug-resistant tuberculosis. Drug-resistant tuberculosis is a major public health concern in many countries. Over the past decade, the number of patients infected with Mycobacterium tuberculosis resistant to the most effective drugs against tuberculosis (ie, rifampicin and isoniazid), which is called multidrug-resistant tuberculosis, has continued to increase. Globally, 4·6% of patients with tuberculosis have multidrug-resistant tuberculosis, but in some areas, like Kazakhstan (...) , Kyrgyzstan, Moldova, and Ukraine, this proportion exceeds 25%. Treatment for patients with multidrug-resistant tuberculosis is prolonged (ie, 9-24 months) and patients with multidrug-resistant tuberculosis have less favourable outcomes than those treated for drug-susceptible tuberculosis. Individualised multidrug-resistant tuberculosis treatment with novel (eg, bedaquiline) and repurposed (eg, linezolid, clofazimine, or meropenem) drugs and guided by genotypic and phenotypic drug susceptibility testing

2019 Lancet

8. Challenges and controversies in childhood tuberculosis. (PubMed)

Challenges and controversies in childhood tuberculosis. Children bear a substantial burden of suffering when it comes to tuberculosis. Ironically, they are often left out of the scientific and public health advances that have led to important improvements in tuberculosis diagnosis, treatment, and prevention over the past decade. This Series paper describes some of the challenges and controversies in paediatric tuberculosis, including the epidemiology and treatment of tuberculosis in children (...) . Two areas in which substantial challenges and controversies exist (ie, diagnosis and prevention) are explored in more detail. This Series paper also offers possible solutions for including children in all efforts to end tuberculosis, with a focus on ensuring that the proper financial and human resources are in place to best serve children exposed to, infected with, and sick from all forms of tuberculosis.Copyright © 2019 Elsevier Ltd. All rights reserved.

2019 Lancet

9. Contact tracing strategies in household and congregate environments to identify cases of tuberculosis in low- and moderate-incidence populations. (PubMed)

Contact tracing strategies in household and congregate environments to identify cases of tuberculosis in low- and moderate-incidence populations. Tuberculosis is an infectious bacterial disease that is spread via respiratory droplets from infected individuals to susceptible contacts. To eliminate this disease from low- and medium-incidence settings, people who are most likely to be infected (contacts) must be identified. Recently, study authors have examined alternate approaches to contact

2019 Cochrane

10. Xpert MTB/RIF and Xpert MTB/RIF Ultra for pulmonary tuberculosis and rifampicin resistance in adults. (PubMed)

Xpert MTB/RIF and Xpert MTB/RIF Ultra for pulmonary tuberculosis and rifampicin resistance in adults. Xpert MTB/RIF (Xpert MTB/RIF) and Xpert MTB/RIF Ultra (Xpert Ultra), the newest version, are the only World Health Organization (WHO)-recommended rapid tests that simultaneously detect tuberculosis and rifampicin resistance in persons with signs and symptoms of tuberculosis, at lower health system levels. A previous Cochrane Review found Xpert MTB/RIF sensitive and specific for tuberculosis (...) (Steingart 2014). Since the previous review, new studies have been published. We performed a review update for an upcoming WHO policy review.To determine diagnostic accuracy of Xpert MTB/RIF and Xpert Ultra for tuberculosis in adults with presumptive pulmonary tuberculosis (PTB) and for rifampicin resistance in adults with presumptive rifampicin-resistant tuberculosis.We searched the Cochrane Infectious Diseases Group Specialized Register, MEDLINE, Embase, Science Citation Index, Web of Science, Latin

2019 Cochrane

11. Interferon gamma release assays for Diagnostic Evaluation of Active tuberculosis (IDEA): test accuracy study and economic evaluation

Interferon gamma release assays for Diagnostic Evaluation of Active tuberculosis (IDEA): test accuracy study and economic evaluation Interferon gamma release assays for Diagnostic Evaluation of Active tuberculosis (IDEA): test accuracy study and economic evaluation Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try (...) , Christopher Partlett 1 , Nathan Green 5, 6, 7, 8 , Aime Boakye 2, 4 , Heather Lambie 2 , Luigi Marongiu 2 , Mark Jit 8, 9 , Peter White 5, 6, 7, 8 , Jonathan J Deeks 1 , Onn Min Kon 2, 4, 10 , Ajit Lalvani 2, 4, * 1 Institute of Applied Health Research, University of Birmingham, Birmingham, UK 2 Tuberculosis Research Centre, National Heart and Lung Institute, Imperial College London, London, UK 3 Department of Clinical Research, London School of Hygiene & Tropical Medicine, London, UK 4 National Institute

2019 NIHR HTA programme

12. Tuberculosis (TB): information for discipline and wing staff

Tuberculosis (TB): information for discipline and wing staff Tuberculosis (TB): Information for discipline and wing staff 2019 Tuberculosis (TB) is an airborne infectious disease that spreads through prolonged contact. TB rates in the UK are on the increase and vulnerable groups, such as people who are in prisons may be at risk. Not all individuals with TB can infect others, only TB affecting the lungs is infectious. Late diagnosis, inadequate treatment, overcrowding, poor ventilation (...) and repeated prison transfers of infectious individuals encourages the spread of TB infection. The prison healthcare staff and your local CCDC are there to support and inform you. Think TB! There are many causes of a persistent cough, the most common of which include viral infection and smoking. A persistent cough can also be a sign of drug misuse (or coming off drugs), tuberculosis or other serious health problems. If an individual in your care has a cough which seems to get worse over a period lasting

2019 Public Health England

13. MVA85A vaccine to enhance BCG for preventing tuberculosis. (PubMed)

MVA85A vaccine to enhance BCG for preventing tuberculosis. Tuberculosis causes more deaths than any other infectious disease globally. Bacillus Calmette-Guérin (BCG) is the only available vaccine, but protection is incomplete and variable. The modified Vaccinia Ankara virus expressing antigen 85A (MVA85A) is a viral vector vaccine produced to prevent tuberculosis.To assess and summarize the effects of the MVA85A vaccine boosting BCG in humans.We searched the Cochrane Infectious Diseases Group (...) Specialized Register; Central Register of Controlled Trials (CENTRAL); MEDLINE (PubMed); Embase (Ovid); and four other databases. We searched the WHO ICTRP and ClinicalTrials.gov. All searches were run up to 10 May 2018.We evaluated randomized controlled trials of MVA85A vaccine given with BCG in people regardless of age or HIV status.Two review authors independently assessed the eligibility and risk of bias of trials, and extracted and analyzed data. The primary outcome was active tuberculosis disease

Full Text available with Trip Pro

2019 Cochrane

14. Tuberculosis. (PubMed)

Tuberculosis. Tuberculosis remains the leading cause of death from an infectious disease among adults worldwide, with more than 10 million people becoming newly sick from tuberculosis each year. Advances in diagnosis, including the use of rapid molecular testing and whole-genome sequencing in both sputum and non-sputum samples, could change this situation. Although little has changed in the treatment of drug-susceptible tuberculosis, data on increased efficacy with new and repurposed drugs have (...) led WHO to recommend all-oral therapy for drug-resistant tuberculosis for the first time ever in 2018. Studies have shown that shorter latent tuberculosis prevention regimens containing rifampicin or rifapentine are as effective as longer, isoniazid-based regimens, and there is a promising vaccine candidate to prevent the progression of infection to the disease. But new tools alone are not sufficient. Advances must be made in providing high-quality, people-centred care for tuberculosis. Renewed

2019 Lancet

15. Adjunctive vitamin D in tuberculosis treatment: meta-analysis of individual participant data

Adjunctive vitamin D in tuberculosis treatment: meta-analysis of individual participant data Randomised controlled trials of adjunctive vitamin D in pulmonary tuberculosis (TB) treatment have yielded conflicting results. Individual participant data meta-analysis could identify factors explaining this variation.We meta-analysed individual participant data from randomised controlled trials of vitamin D in patients receiving antimicrobial therapy for pulmonary TB. Primary outcome was time

2019 EvidenceUpdates

16. Efficacy of acupressure to prevent adverse reactions to anti-tuberculosis drugs: Randomized controlled trials

Efficacy of acupressure to prevent adverse reactions to anti-tuberculosis drugs: Randomized controlled trials To determine whether acupressure can prevent or relieve the adverse drug reactions (ADRs) of anti-tuberculosis drugs.People receiving drug treatment for TB often experience ADRs that may cause them to stop taking their medication. Acupressure is a form of traditional Chinese medicine that can be applied to alleviate or prevent disease symptoms.A double-blinded, repeated-measures (...) clinical trial in hospitals in Taiwan was carried out from April 2015 - May 2017.Convenience sampling was used to select 32 people (15 for the experimental group and 17 for the control group) aged >20 years who were taking anti-tuberculosis drugs. The people were randomized to receive 4-week of true acupressure and 4-weeks of sham acupressure. Acupressure therapy was given by a researcher in all cases. Both groups received treatment once per day on weekdays, with 15 min for each acupressure session

2019 EvidenceUpdates

17. Yield and Efficiency of Novel Intensified Tuberculosis Case-Finding Algorithms for People Living with HIV

Yield and Efficiency of Novel Intensified Tuberculosis Case-Finding Algorithms for People Living with HIV The recommended tuberculosis (TB) intensified case finding (ICF) algorithm for people living with HIV (symptom-based screening followed by Xpert MTB/RIF [Xpert] testing) is insufficiently sensitive and results in unnecessary Xpert testing.To evaluate whether novel ICF algorithms combining C-reactive protein (CRP)-based screening with urine Determine TB-LAM (TB-LAM), sputum Xpert

2019 EvidenceUpdates

18. One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis. (PubMed)

One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis. Tuberculosis is the leading killer of patients with human immunodeficiency virus (HIV) infection. Preventive therapy is effective, but current regimens are limited by poor implementation and low completion rates.We conducted a randomized, open-label, phase 3 noninferiority trial comparing the efficacy and safety of a 1-month regimen of daily rifapentine plus isoniazid (1-month group) with 9 months of isoniazid alone (9 (...) -month group) in HIV-infected patients who were living in areas of high tuberculosis prevalence or who had evidence of latent tuberculosis infection. The primary end point was the first diagnosis of tuberculosis or death from tuberculosis or an unknown cause. Noninferiority would be shown if the upper limit of the 95% confidence interval for the between-group difference in the number of events per 100 person-years was less than 1.25.A total of 3000 patients were enrolled and followed for a median

2019 NEJM

19. A Trial of a Shorter Regimen for Rifampin-Resistant Tuberculosis. (PubMed)

A Trial of a Shorter Regimen for Rifampin-Resistant Tuberculosis. Cohort studies in Bangladesh showed promising cure rates among patients with multidrug-resistant tuberculosis who received existing drugs in regimens shorter than that recommended by the World Health Organization (WHO) in 2011.We conducted a phase 3 noninferiority trial in participants with rifampin-resistant tuberculosis that was susceptible to fluoroquinolones and aminoglycosides. Participants were randomly assigned, in a 2:1 (...) ratio, to receive a short regimen (9 to 11 months) that included high-dose moxifloxacin or a long regimen (20 months) that followed the 2011 WHO guidelines. The primary efficacy outcome was a favorable status at 132 weeks, defined by cultures negative for Mycobacterium tuberculosis at 132 weeks and at a previous occasion, with no intervening positive culture or previous unfavorable outcome. An upper 95% confidence limit for the between-group difference in favorable status that was 10 percentage

2019 NEJM

20. Smartphone-enabled video-observed versus directly observed treatment for tuberculosis: a multicentre, analyst-blinded, randomised, controlled superiority trial. (PubMed)

Smartphone-enabled video-observed versus directly observed treatment for tuberculosis: a multicentre, analyst-blinded, randomised, controlled superiority trial. Directly observed treatment (DOT) has been the standard of care for tuberculosis since the early 1990s, but it is inconvenient for patients and service providers. Video-observed therapy (VOT) has been conditionally recommended by WHO as an alternative to DOT. We tested whether levels of treatment observation were improved with VOT.We (...) did a multicentre, analyst-blinded, randomised controlled superiority trial in 22 clinics in England (UK). Eligible participants were patients aged at least 16 years with active pulmonary or non-pulmonary tuberculosis who were eligible for DOT according to local guidance. Exclusion criteria included patients who did not have access to charging a smartphone. We randomly assigned participants to either VOT (daily remote observation using a smartphone app) or DOT (observations done three to five

Full Text available with Trip Pro

2019 Lancet